Avadhani, Radhika
Ziai, Wendy C.
Thompson, Richard E.
Mould, W. Andrew
Lane, Karen
Nanni, Angeline
Iacobelli, Michael
Sharrock, Matthew F.
Sansing, Lauren H.
Van Eldik, Linda J.
Hanley, Daniel F. http://orcid.org/0000-0002-9536-4258
Lord, Aaron
Liptrap, Elizabeth
Zuccarello, Mario
Hatton, Kevin
Girotra, Tarun
Chang, Tiffany
Mascitelli, Justin
Magid-Bernstein, Jessica
Babi, Marc
,
Funding for this research was provided by:
National Institute on Aging (R01AG069930)
National Center for Advancing Translational Sciences (U24TR001609)
Article History
Received: 5 June 2023
Accepted: 22 September 2023
First Online: 2 November 2023
Conflict of interest
: Dr. Ziai reports grants from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke; consulting fees from Lumosa Therapeutics and <i>Neurocritical Care</i>, for which she is an associate editor; meeting support from Integra; DSMB participation for C.R. Bard; and a leadership role in the Neurocritical Care Society as Neurocritical Care Research Central co-director. Dr. Thompson reports statistical consulting for Op2Lysis, a company testing a drug similar to MW189. Dr. Sansing reports grants from the National Institutes of Health and the American Heart Association. Dr. Van Eldik is an inventor on patents covering MW189 and a scientific founder of ImmunoChem Therapeutics LLC, a start-up formed to commercialize MW189. Her institution, University of Kentucky, might benefit if MW189 is successful commercially. Dr. Hanley reports grants from the National Institutes of Health and personal fees from Neurelis, Neurotrope, and medicolegal consulting.
: The Johns Hopkins Medicine IRB, serving as the single IRB, approved the study design. The trial will be conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and all applicable regulatory requirements. Written informed consent will be obtained from all participants or their legally authorized representatives.
: ClinicalTrials.gov identifier NCT05020535.